Newsfeed

Passage Of Stop Gap Measure In Limbo

The passage of a government shutdown bill is now in limbo after a group of House Republicans as well as President-elect Donald Trump, VP-elect JD Vance, Elon Musk, and Vivek Ramaswamy came out against the measure, arguing it is irresponsible and not a straight government-funding extension.

The bill includes provisions to bolster the accuracy and reliability of Medicare Advantage (MA) provider directories and cost-sharing protections for those who receive care from out-of-network providers due to inaccuracies in those directories.

The bill also includes reform of pharmacy benefit managers’ practices in Medicare, Medicaid and the commercial market and reforming so-called patent thickets to delay generic competition.

Trump and Vance also argue the debt ceiling should be raised under Biden’s watch to avoid issues with Democratic support in 2025.

In other news, the final health piece of the bill left out site-neutral payments and prior authorization reforms.

House Democrats have said they will not support a clean CR to keep government operating.

Additional articles: https://www.fiercehealthcare.com/payers/how-healthcare-orgs-are-reacting-proposed-government-funding-bill and https://www.modernhealthcare.com/politics-policy/donald-trump-government-spending-bill-debt-ceiling and https://insidehealthpolicy.com/daily-news/congress-moves-forward-25-physician-pay-fix-omits-site-neutral-prior-auth-reforms and https://insidehealthpolicy.com/daily-news/trump-jeopardizes-two-year-telehealth-extension-broader-health-deal and https://insidehealthpolicy.com/daily-news/medicare-advantage-ghost-network-reforms-risk-trump-urges-lawmakers-oppose-cr and https://insidehealthpolicy.com/inside-drug-pricing-daily-news/cr-flux-pbm-generic-drug-transparency-drug-patent-reforms-uncertain and https://thehill.com/homenews/administration/5047382-trump-government-spending-deal/ and https://thehill.com/homenews/house/5047510-hakeem-jeffries-democrats-government-funding/

(Some articles may require a subscription.)

#governmentshutdown #crs #healthcare

https://thehill.com/homenews/house/5047285-mike-johnson-spending-plan-b

Read More »

PBMs Took Payments From Drug Makers During Opioid Crisis

A New York Times multi-part expose continues its attacks on the pharmacy benefits manager (PBM) industry. In its latest investigation, the newspaper tells us that PBMs took payments from opioid manufacturers in return for not restricting the flow of pills. PBMs collected billions while tens of thousands overdosed and died from the prescription painkillers. Among the drug manufacturer payors was Purdue Pharma and the disgraced Sackler Family.

Slowly but surely the roles of various drug channel stakeholders have come to light, from drug makers to wholesalers to PBMs to pharmacies. It is a national tragedy stoked by greed. All of the corruption needs to come to light and violators civilly and criminally held to account.

The report is sure to turn up the heat even more on PBMs on Capitol Hill.

(Article may require a subscription.)

#nyt #opioids #branddrugmakers #pbms

https://www.nytimes.com/2024/12/17/business/pharmacy-benefit-managers-opioids.html

Read More »

CR and Healthcare Policy Bill Updates

Capitol Hill lawmakers are inching toward a continuing resolution (CR) that needs to be adopted by the end of the week. At the same time, Congress looks like it has agreed to a critical bill to extend certain healthcare programs set to expire at year’s end. Telehealth extensions will be for two years, while the hospital at home program will get a five-year extension. Medicare docs will get a 2.5% hike in 2025 vs. a 2.8% cut. At least a dozen other healthcare areas get fixes or increases under the bill.

In a bombshell, there are major offsets to pay for increases, including major pharmacy benefits manager (PBM) reforms.

  • A “delinking” policy to require that Part D Plan sponsors delink PBM compensation from the price of the drug.
  • Prohibition on PBM “spread pricing” in Medicaid.
  • Medicare Part D transparency requirements for PBMs and Medicare Part D.
  • Private Insurance PBM reforms.

Reports also suggest that Medicare Advantage (MA) prior authorization reforms are or may be included. These could include some or all of the provisions in the Improving Seniors’ Timely Access to Care Act.

The PBM trade lobby, the Pharmaceutical Care Management Association (PCMA), issued a vociferous response to reports, arguing the changes will increase costs to the government, employers, and consumers. Specifically, it says the delinking reform would increase premiums in Part D by $13 billion and will benefit drug companies.

In other news, an interesting article on the state of traditional PBMs and those dedicated to transparency. President-elect Trump declared last week he would support reform of PBMs. Major companies with PBMs saw their stocks drop on the declaration.

Additional articles: https://thehill.com/business/budget/5042654-government-funding-deal-progress/ and https://insidehealthpolicy.com/daily-news/lawmakers-close-health-package-includes-two-year-telehealth-extension and https://www.fiercehealthcare.com/payers/pbm-lobby-punches-back-end-year-package and https://insidehealthpolicy.com/daily-news/pbm-lobby-blasts-reported-inclusion-delinking-private-market-transparency-policies and https://www.fiercehealthcare.com/payers/2025-outlook-alternative-pbms-look-heap-pressure-industry-titans and https://www.modernhealthcare.com/politics-policy/cvs-unitedhealth-cigna-shares-pbms-donald-trump-middlemen

(Some articles may require a subscription.)

#crs #governmentshutdown #healthcare #pbms #drugpricing #hospitalathome #telehealth #medicareadvantage #partd #pdp #medicaid #physicians #rates #trump

https://www.fiercehealthcare.com/regulatory/two-year-extension-telehealth-likely-negotiations-crest-congress

Read More »

UnitedHealth CEO Admits Frustration Is Understandable

UnitedHealth Group CEO Andrew Witty published an opinion piece in The New York Times today where he acknowledged the rage that has surfaced in the aftermath of the death of his deputy. Witty said health plans play a role in the issues. Witty stated: “We know the health system does not work as well as it should, and we understand people’s frustrations with it.”

Oscar Health CEO Mark Bertolini, who once ran Aetna before its merger with CVS Health, also said that anger at the healthcare system is “justified.” Bertolini says he would eliminate employer-sponsored insurance because employers have little leverage. He thinks that migrating to individual coverage would be better. Oscar is focused on the individual market.

While I understand Witty’s statement in light of what occurred, I think insurers are an actor in a very dysfunctional system. Health plans alone are not the culprits. See my blog here: https://www.healthcarelabyrinth.com/i-am-shocked-by-the-vitriol-post-unitedhealthcare-executives-assassination/

In other news, Pro Publica obtained a UnitedHealthcare playbook that seeks to limit the coverage of autism.

Additional articles: https://www.modernhealthcare.com/insurance/unitedhealth-group-andrew-witty-brian-thompson-nyt-op-ed  and https://thehill.com/policy/healthcare/5039515-oscar-health-ceo-employer-healthcare-unitedhealthcare-shooting/?tbref=hp and https://thehill.com/policy/healthcare/5039630-unitedhealth-ceo-defends-healthcare/ and https://www.fiercehealthcare.com/payers/unitedhealth-strategically-limiting-access-critical-treatment-kids-autism

(Some articles may require a subscription.)

#unitedhealthcare #oscar #tragedy

https://www.fiercehealthcare.com/payers/unitedhealth-group-ceo-acknowledges-outpouring-frustration-healthcare

Read More »

Centene Earnings Guidance Released For 2025

Centene released its earnings guidance for 2025 at its investor day. Centene says revenue will be between $166.5 billion and $169.5 billion. It says utilization will continue to be elevated and its medical loss ratio (MLR) will be between 88.4% and 89%.

Centene reaffirmed that it expects to bring in between $143.5 billion and $144.5 billion in premium and service revenue for 2024. Its MLR will be between 88.3% and 88.5% for this year.

Centene expects to lose $250 million on Medicare Advantage (MA) this year but intends to break even by 2027. It also lost 20% of its MA enrollment during the 2025 enrollment season that just concluded.

Centene will gain $200 million in additional MA Star Ratings bonus payments in 2026 after the Centers for Medicare and Medicaid Services (CMS) revised its ratings.

Additional articles: https://www.modernhealthcare.com/insurance/centene-medicare-advantage-ratings-investor-sarah-london and https://www.beckerspayer.com/policy-updates/centenes-predictions-for-trump-administration-policy-3-things-to-know.html

(Some articles may require a subscription.)

#centene #medicareadvantage #medicaid #managedcare

https://www.fiercehealthcare.com/payers/centene-expects-earn-least-1665b-revenue-2025

Read More »

Bipartisan Bills Seek PBM Divestitures From Health Plans

More evidence that some kind of pharmacy benefits manager (PBM) reform is coming on Capitol Hill: Democratic and Republican lawmakers now have bills to have health plans divest their PBMs. In the Senate, the bill is co-led by a very unlikely pair – liberal Sen. Elizabeth Warren, D-MA, and conservative Sen. Josh Hawley, R-MO. In the House, a companion bill is sponsored by Rep. Jake Auchincloss, D-MA. and Diana Harshbarger, R-TN. Hawley is among those anti-corporate welfare Republicans who are getting more active on healthcare issues.

The Patients Before Monopolies Act of 2024 would require insurers to sell off their PBMs within three years. The bill also would prohibit corporations that own PBMs or health plans from also owning pharmacies.

Other PBM reform proposals continue to gain bipartisan momentum. Some changes could come in the end-of-year stop-gap bill or sometime in 2025.

Additional articles: https://www.modernhealthcare.com/politics-policy/pbm-act-cvs-unitedhealth-cigna-elizabeth-warren-josh-hawley and https://www.healthcaredive.com/news/pbm-act-force-pharmacy-sales-introduced-unitedhealth-cigna-cvs/735233/ and https://thehill.com/policy/healthcare/5035450-bipartisan-lawmakers-want-to-force-health-insurers-pbms-to-sell-off-pharmacies/

(Some articles may require a subscription.)

#pbms #healthplans #drugpricing

https://www.fiercehealthcare.com/payers/warren-hawley-introduce-bill-requiring-insurers-offload-pbm-businesses

Read More »

Democrats Ramping Up Opposition To Mehmet Oz For CMS Administrator

Democrats are beginning to ramp up efforts in opposition to Mehmet Oz as Administrator of the Centers for Medicare and Medicaid Services (CMS). Democrats question the numerous investments he holds, including in UnitedHealth Group. As well, they question his previous endorsement of Medicare Advantage for All, which would enroll those currently covered by private insurance, all Medicare beneficiaries, and the uninsured in Medicare Advantage (MA). Oz now says he favors expansion of MA not a radical healthcare transformation.

Additional articles: https://insidehealthpolicy.com/daily-news/senate-democrats-scrutinize-oz-s-ma-all-proposal-insurance-ties and https://thehill.com/policy/healthcare/5032680-warren-democrats-oz-medicare-privatization/

(Some articles may require a subscription.)

#medicareadvantage #medicare #oz #trump

https://www.modernhealthcare.com/politics-policy/dr-oz-medicare-advantage-investments-elizabeth-warren-ron-wyden

Read More »

Trump Wants PBM Reform

Pressure is mounting to pass pharmacy benefits manager (PBM) reform. Donald Trump came out over the weekend in favor of PBM reform. Brand drug makers have gotten to Trump, getting him to focus on PBMs rather than high brand drug prices at the beginning of the drug channel. Discussions are occurring on whether PBM reform should go in the lame-duck session bill.

(Article may require a subscription.)

#pbms #drugpricing

https://insidehealthpolicy.com/inside-drug-pricing-daily-news/trump-pegs-pbm-reform-priority-wyden-pushes-hard-lame-duck-reforms

Read More »

KFF Finds Spending Higher When MA Enrollees Return To Traditional Medicare

A new analysis from Kaiser Family Foundation (KFF) finds higher Medicare spending among those who switch from Medicare Advantage (MA) to traditional Medicare as compared with similar beneficiaries who were in traditional Medicare all along.

KFF says Medicare spent an average of 27% more on those switching in, after adjusting for differences in health status and other characteristics. This amounts to a difference of $2,585 in Medicare spending per person, on average, between the two groups in 2022.

The difference in spending among people with certain health conditions varied from 15% for those with pneumonia to 34% for people with diabetes.

The causes for the higher spending are as follows: skilled nursing facility spending (34%), outpatient hospital spending (23%), and inpatient hospital spending (20%).

Differences in spending were greater for people of color and dual eligibles and increased with age.

KFF asks several questions on the reasons why spending is higher:

  • Were switchers unable to get the medical care they felt they needed while enrolled in MA?
  • Would more MA enrollees make the switch if people with pre-existing conditions did not face barriers to purchasing Medicare supplemental insurance?
  • Do the disenrollments reduce costs and increase profits for MA plans?
  • Does the current MA payment system adequately account for adverse selection into traditional Medicare?

KFF notes that previous KFF and MedPAC, the congressional policy arm, analyses found that people who enroll in MA have lower Medicare spending in the years before they enroll than similar people who remain in traditional Medicare, even after controlling for health status.

I don’t discount that some of the increased costs could come from higher needs of individuals and the potential to receive the care they think they need. But I would also argue that KFF has not covered the fact that MA is more efficient and seems to assume that all the increased spending is in the traditional program is absolutely justified.

Utilization management in MA is not a bad thing. As an example, the highest increased cost area is skilled nursing facility (SNF) care post acute stays. But there is every reason to believe that providers in traditional Medicare are doling out orders for SNF stays without really determining if lower costs of care could serve members just as well. The same holds true for even more expensive inpatient stays.

MA plans’ rate of inpatient (IP) stays and SNF stays has been markedly less. With a 2024 prior authorization change, MA IP and SNF stay costs will likely increase over time as the Centers for Medicare and Medicaid Services (CMS) have told MA plans to abide by the traditional program rules.

In essence, they took the managed care out of managed care. While KFF is largley balanced, it shows some of its anti-MA and big healthcare bias here. This is sure to be used on Capitol Hill and the industry has to be ready to push back.

Press release: https://www.kff.org/medicare/press-release/medicare-spent-an-average-of-27-more-on-people-who-switched-from-medicare-advantage-to-traditional-medicare-compared-to-those-who-were-only-in-traditional-medicare/

#kff #medicareadvantage #medicare #priorauthorization #coverage

https://www.kff.org/medicare/issue-brief/medicare-spending-was-27-percent-more-for-people-who-disenrolled-from-medicare-advantage-than-for-similar-people-in-traditional-medicare/

Read More »

Primary Care Market To Shift by 2023

A Bain & Company study on primary care suggests non-traditional providers, including retailers, payers, and advanced primary care providers, are expected to capture 30% of the U.S. primary care market by 2030. Bain says payers will continue to invest in primary care and population-focused models and will capture 20% of the market. How retailers will fare is more of a question. Bain also says providers will pivot to and grow their value-based care focus.

#primarycare #healthplans #insurers #providers

https://www.fiercehealthcare.com/providers/primary-care-market-will-see-major-shifts-2030-payers-nontraditional-providers-gain

Read More »

Available Now

$30.00